Injective co-founder and CEO Eric Chen said he expects U.S. exchange-traded funds tied to the Layer 1 network's native token INJ to launch before 2027, stating that 2027 is "a little bit too far." He added that the timeline is "way sooner than I expected as well." There are currently two ETF applications tied to INJ, the 21Shares Injective ETF and the Canary Staked INJ ETF, both of which submitted amended S-1 registration statements in September, signaling progress in the application process.